VivoSeq
Other

B-Cell

1

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

B-Cell is an early-stage landscape with 1 program across 1 company. The most active players are Novartis.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells

National Cancer Institute (NCI)

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

7

clinical trials

Completed4 · 57%
Recruiting1 · 14%
Terminated1 · 14%
Active, not recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies
Recruiting·HHeinrich-Heine University, Duesseldorf·N/A·NCT06586177·100 enrolled
A Retrospective Observational Study of the Safety and Efficacy of Intensified Chemotherapy Regimens in Aggressive B-cell Lymphomas With MYC Rearrangement
Active, not recruiting·IIRCCS San Raffaele·N/A·NCT07663175·500 enrolled
Epidemiologic Study of Persistent Polyclonal B-cell Lymphocytosis (PPBL)
Completed·—·N/A·NCT03296046·100 enrolled
Synergetic B-cell Immodulation in SLE
Completed·LLeiden University Medical Center·Phase 2·NCT02284984·16 enrolled
ADCC Mediated B-Cell dEpletion and BAFF-R Blockade
Completed·Novartis logoNovartis·Phase 2/3·NCT03217422·68 enrolled
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
Completed·National Cancer Institute (NCI)·Phase 1·NCT01087294·85 enrolled
Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL
Terminated·—·Phase 1·NCT04803123·3 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)